Abstract:Abstract Background Identifying immunogens which can elicit effective T cell responses against human immunodeficiency virus type 1 (HIV-1) is important for developing a T-cell based vaccine. It has been reported that human leukocyte antigen (HLA)-B*13-restricted T-cell responses contributed to HIV control in subtype B′ and C infected individuals. However, the kinetics of B*13-restricted T-cell responses, viral evolution within epitopes, and the impact on disease progression in CRF01_AE subtype HIV-1-infected men who have sex with men (MSM) are not known. Results Interferon-γ ELISPOT assays and deep sequencing of viral RNAs were done in 14 early HLA-B*13-positive CRF01_AE subtype HIV-1-infected MSM. We found that responses to RQEILDLWV (Nef 106–114 , RV9), GQMREPRGSDI (Gag 226–236 , GI11), GQDQWTYQI (Pol 487–498 , GI9), and VQNAQGQMV (Gag 135–143 , VV9) were dominant. A higher relative magnitude of Gag-specific T-cell responses, contributed to viral control, whereas Nef-specific T-cell responses were associated with rapid disease progression. GI11 (Gag) was conserved and strong GI11 (Gag)-specific T-cell responses showed cross-reactivity with a dominant variant, M228I, found in 3/12 patients; GI11 (Gag)-specific T-cell responses were positively associated with CD4 T-cell counts ( R = 0.716, P = 0.046). Interestingly, the GI9 (Pol) epitope was also conserved, but GI9 (Pol)-specific T-cell responses did not influence disease progression ( P > 0.05), while a D490G variant identified in one patient did not affect CD4 T-cell counts. All the other epitopes studied [VV9 (Gag), RQYDQILIEI (Pol 113–122 , RI10), HQSLSPRTL (Gag 144–152 , HL9), and RQANFLGRL (Gag 429–437, RL9)] developed escape mutations within 1 year of infection, which may have contributed to overall disease progression. Intriguingly, we found early RV9 (Nef)-specific T-cell responses were associated with rapid disease progression, likely due to escape mutations. Conclusions Our study strongly suggested the inclusion of GI11 (Gag) and exclusion of RV9 (Nef) for T-cell-based vaccine design for B*13-positive CRF01_AE subtype HIV-1-infected MSM and high-risk individuals.

Antibody persistence and T-cell balance: Two key factors confronting HIV vaccine development

Anti–HIV-1 B cell responses are dependent on B cell precursor frequency and antigen-binding affinity

Beyond glycan barriers: non-cognate ligands and protein mimicry approaches to elicit broadly neutralizing antibodies for HIV-1

HIV Vaccine Development at a Crossroads: New B and T Cell Approaches

Ontogeny‐based immunogens for the induction of V2‐directed HIV broadly neutralizing antibodies

A Remarkable Genetic Shift in a Transmitted/Founder Virus Broadens Antibody Responses Against HIV-1

Antibody-based Candidate Therapeutics Against HIV-1: Implications for Virus Eradication and Vaccine Design

Aiming for protective T-cell responses: a focus on the first generation conserved-region HIVconsv vaccines in preventive and therapeutic clinical trials

Enhancing anti-viral neutralization response to immunization with HIV-1 envelope glycoprotein immunogens

Lack of Protection Following Passive Transfer of Polyclonal Highly Functional Low-Dose Non-Neutralizing Antibodies

Tailoring T fh profiles enhances antibody persistence to a clade C HIV-1 vaccine in rhesus macaques

Enhancement of Human Immunodeficiency Virus Type 1 Infection by Antisera to Peptides from the Envelope Glycoproteins Gp120/gp41.

Production of HIV-1 Env-specific antibodies mediating innate immune functions depends on cognate IL-21- secreting CD4+ T cells

Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus

Epitope-vaccine strategy against HIV-1: today and tomorrow.

Understanding the Mechanisms and Limitations of Immune Control of HIV

Anti-Immune Complex Antibodies are Elicited During Repeated Immunization with HIV Env Immunogens

Identification and specificity of broadly neutralizing antibodies against HIV

A longitudinal analysis of immune escapes from HLA-B*13-restricted T-cell responses at early stage of CRF01_AE subtype HIV-1 infection and implications for vaccine design

Identification of Effective Subdominant Anti-HIV-1 CD8+ T Cells Within Entire Post-infection and Post-vaccination Immune Responses